These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 2113611

  • 21. The antifracture efficacy of alendronate.
    Seeman E.
    Int J Clin Pract Suppl; 1999 Apr; 101():40-5. PubMed ID: 12675021
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH.
    N Engl J Med; 2001 May 10; 344(19):1434-41. PubMed ID: 11346808
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. 36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis.
    Sebaldt RJ, Ioannidis G, Adachi JD, Bensen WG, Bianchi F, Cividino A, Gordon M, Kaminska E, Scocchia T, Petrie A, Stephenson GF, Goldsmith CH.
    J Rheumatol; 1999 Jul 10; 26(7):1545-9. PubMed ID: 10405943
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate.
    Iwamoto J, Takeda T, Ichimura S.
    J Orthop Sci; 2001 Jul 10; 6(6):487-92. PubMed ID: 11793169
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women.
    Dawson-Hughes B, Dallal GE, Krall EA, Sadowski L, Sahyoun N, Tannenbaum S.
    N Engl J Med; 1990 Sep 27; 323(13):878-83. PubMed ID: 2203964
    [Abstract] [Full Text] [Related]

  • 31. [Etidronate].
    Inui K, Takaoka K.
    Nihon Rinsho; 2003 Feb 27; 61(2):226-30. PubMed ID: 12638212
    [Abstract] [Full Text] [Related]

  • 32. Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis.
    Ott SM, Woodson GC, Huffer WE, Miller PD, Watts NB.
    J Clin Endocrinol Metab; 1994 Apr 27; 78(4):968-72. PubMed ID: 8157728
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Etidronate and alendronate in the treatment of postmenopausal osteoporosis.
    Beauchesne MF, Miller PF.
    Ann Pharmacother; 1999 May 27; 33(5):587-99. PubMed ID: 10369624
    [Abstract] [Full Text] [Related]

  • 35. Cyclical etidronate versus sodium fluoride in established postmenopausal osteoporosis: a randomized 3 year trial.
    Guañabens N, Farrerons J, Perez-Edo L, Monegal A, Renau A, Carbonell J, Roca M, Torra M, Pavesi M.
    Bone; 2000 Jul 27; 27(1):123-8. PubMed ID: 10865219
    [Abstract] [Full Text] [Related]

  • 36. Daily and cyclic parathyroid hormone in women receiving alendronate.
    Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R.
    N Engl J Med; 2005 Aug 11; 353(6):566-75. PubMed ID: 16093465
    [Abstract] [Full Text] [Related]

  • 37. Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate.
    Ringe JD, Kipshoven C, Cöster A, Umbach R.
    Osteoporos Int; 1999 Aug 11; 9(2):171-8. PubMed ID: 10367046
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment.
    Montessori ML, Scheele WH, Netelenbos JC, Kerkhoff JF, Bakker K.
    Osteoporos Int; 1997 Aug 11; 7(1):52-8. PubMed ID: 9102064
    [Abstract] [Full Text] [Related]

  • 40. Predicting subsequent bone density response to intermittent cyclical therapy with etidronate from initial density response in patients with osteoporosis.
    Crilly RG, Sebaldt RJ, Hodsman AB, Adachi JD, Brown JP, Goldsmith CH, Hanley DA, Olszynski WO, Ste-Marie LG, Stephenson GF.
    Osteoporos Int; 2000 Aug 11; 11(7):607-14. PubMed ID: 11069195
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.